Oral oxaborole MRX-5 exhibits efficacy against pulmonary Mycobacterium abscessus in mouse
Antimicrobial Agents and Chemotherapy · 2024
DOI: 10.1128/aac.01351-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von Binayak Rimal und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Mycobacterium abscessus, Mycobacterium Infections, Nontuberculous. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MicuRx Pharmaceuticals, Inc.
Abstract (Originalsprache)
Mycobacterium abscessus (Mab ) is an opportunistic pathogen common in patients with lung comorbidities and immunosuppression. There are no FDA-approved treatments, and current treatment has a failure rate exceeding 50%. The intravenous oxaborole MRX-6038 is active against Mab . This study evaluated MRX-5, the oral prodrug, against five Mab isolates in a mouse lung infection model. MRX-5 showed dose-dependent efficacy, with 15 and 45 mg/kg doses comparable to the standard of care, supporting progression to clinical trial.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Infectious Diseases, Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
- MicuRx Pharmaceuticals, Inc., Foster City, California, USA.
- Center for Nontuberculous Mycobacteria and Bronchiectasis, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
ORCID-Profile: Gyanu Lamichhane
Förderung
- MicuRx Pharmaceuticals, Inc
Zitieren
APA
Rimal, B., Howe, R. A., Panthi, C. M., Wang, W., & Lamichhane, G. (2024). Oral oxaborole MRX-5 exhibits efficacy against pulmonary Mycobacterium abscessus in mouse. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01351-24
Vancouver
Rimal B, Howe RA, Panthi CM, Wang W, Lamichhane G. Oral oxaborole MRX-5 exhibits efficacy against pulmonary Mycobacterium abscessus in mouse. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.01351-24
BibTeX
@article{Rimal2024,
author = {Rimal, Binayak and Howe, Ruth A and Panthi, Chandra M and Wang, Wen and Lamichhane, Gyanu},
title = {Oral oxaborole MRX-5 exhibits efficacy against pulmonary Mycobacterium abscessus in mouse},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2024},
doi = {10.1128/aac.01351-24}
}
EUVIMED